Molecular Diagnosis & Therapy

, Volume 12, Issue 2, pp 77–85 | Cite as

Early Detection of Colon Cancer

New Tests on the Horizon
  • Akshay K. Gupta
  • Dean E. Brenner
  • D. Kim Turgeon


This year, the American Cancer Society reported that the rate of decline in both the incidence and mortality of colorectal cancer has increased over the last two decades. This success is felt to be attributable to the early detection and treatment of colonic adenomas and early-stage colorectal cancers. However, the current recommended ‘menu of options’ for screening is limited by poor patient acceptance, low sensitivity, and both high cost and poor accessibility for application to a large general screening population (colonoscopy). Computerized tomography and magnetic resonance colonography offer an alternative method for the identification of polyps and early lesions in certain patients, but have cost, access, and acceptance limitations that are similar to those of colonoscopy; thus, they present similar barriers to their use in broad population screening. These limitations provide a strong rationale for the development of early colorectal cancer detection biomarkers that are simple to use and are cost effective.

A successful biomarker or biomarker panel, coupled with the colonoscopic follow-up of only those patients with positive results, would reduce the burden and morbidity associated with the screening of colonoscopy. This would most likely result in enhanced adherence to colorectal screening, as well as a dramatic reduction in the incidence and mortality rates of colorectal cancer. In this paper, we review recent advances in the discovery of potential colorectal cancer biomarkers. Their applicability to clinical population screening will require large prospective validation.


  1. 1.
    American Cancer Society. Cancer facts and figures 2008 [online]. Available from URL: [Accessed 2008 Feb 25]
  2. 2.
    Meissner HI, Breen N, Klabunde CN, et al. Patterns of colorectal cancer screening uptake among men and women in the United States. Cancer Epidemiol Biomarkers Prev2006; 15(2): 389–94PubMedCrossRefGoogle Scholar
  3. 3.
    CDC. National colorectal awareness month: March 2008. Morb Mortal Wkly Rep 2008 Mar 14; 57 (10): 1 [online]. Available from URL: [Accessed 2008 Mar 31]
  4. 4.
    US Department of Health and Human Services. The guide to clinical preventive services 2006: recommendations of the US preventive Services Task Force. Rockville (MD): United Health Foundation, 2006 [online]. Available from URL: [Accessed 2008 Mar 7]
  5. 5.
    American Cancer Society. American Cancer Society guidelines on screening and surveillance for the early detection of adenomatous polyps and colorectal cancer: 2001. Altanta (GA): American Cancer Society, 2001Google Scholar
  6. 6.
    Hurlstone DP, Karajeh M, Sanders DS, et al. Rectal aberrant crypt foci identified using high-magnification-chromoscopic colonoscopy: biomarkers for flat and depressed neoplasia. Am J Gastroenterol 2005; 100(6): 1283–9PubMedCrossRefGoogle Scholar
  7. 7.
    Chen WD, Han ZJ, Skoletsky J, et al. Detection in fecal DNA of colon cancer-specific methylation of the nonexpressed vimentin gene. J Natl Cancer Inst 2005; 97(15): 1124–32PubMedCrossRefGoogle Scholar
  8. 8.
    Lieberman DA, Weiss DG, Bond JH, et al. Use of colonoscopy to screen asymptomatic adults for colorectal cancer. Veterans Affairs Cooperative Study Group 380. N Engl J Med 2000; 343(3): 162–8PubMedCrossRefGoogle Scholar
  9. 9.
    Davies RJ, Miller R, Coleman N. Colorectal cancer screening: prospects for molecular stool analysis. Nat Rev Cancer 2005; 5(3): 199–209PubMedCrossRefGoogle Scholar
  10. 10.
    Rockey DC, Koch J, Yee J, et al. Prospective comparison of air-contrast barium enema and colonoscopy in patients with fecal occult blood: a pilot study. Gastrointest Endosc 2004; 60(6): 953–8PubMedCrossRefGoogle Scholar
  11. 11.
    Cotton PB, Durkalski VL, Pineau BC, et al. Computed tomographic colonography (virtual colonoscopy): a multicenter comparison with standard colonoscopy for detection of colorectal neoplasia. JAMA 2004; 291(14): 1713–9PubMedCrossRefGoogle Scholar
  12. 12.
    Mulhall BP, Veerappan GR, Jackson JL. Meta-analysis: computed tomographic colonography. Ann Intern Med 2005; 142(8): 635–50PubMedGoogle Scholar
  13. 13.
    Florie JJ, Birnie EE, van Gelder RERE, et al. MR colonography with limited bowel preparation: patient acceptance compared with that of full-preparation colonoscopy. Radiology 2007; 245(1): 150–9PubMedCrossRefGoogle Scholar
  14. 14.
    Florie JJ, Jensch SS, Nievelstein RARAJ, et al. MR colonography with limited bowel preparation compared with optical colonoscopy in patients at increased risk for colorectal cancer. Radiology 2007; 243(1): 122–31PubMedCrossRefGoogle Scholar
  15. 15.
    Vijan S, Inadomi J, Hayward RA, et al. Projections of demand and capacity for colonoscopy related to increasing rates of colorectal cancer screening in the United States. Aliment Pharmacol Ther 2004; 20(5): 507–15PubMedCrossRefGoogle Scholar
  16. 16.
    Gupta AK, Pretlow TP, Schoen RE. Aberrant crypt foci: what we know and what we need to know. Clin Gastroenterol Hepatol 2007; 5(5): 526–33PubMedCrossRefGoogle Scholar
  17. 17.
    Bird RP. Observation and quantification of aberrant crypts in the murine colon treated with a colon carcinogen: preliminary findings. Cancer Lett 1987; 37(2): 147–51PubMedCrossRefGoogle Scholar
  18. 18.
    Pretlow TP, Barrow BJ, Ashton WS, et al. Aberrant crypts: putative preneoplastic foci in human colonic mucosa. Cancer Res 1991; 51(5): 1564–7PubMedGoogle Scholar
  19. 19.
    Yokota T, Sugano K, Kondo H, et al. Detection of aberrant crypt foci by magnifying colonoscopy. Gastrointest Endosc 1997; 46(1): 61–5PubMedCrossRefGoogle Scholar
  20. 20.
    McLellan EA, Bird RP. Specificity study to evaluate induction of aberrant crypts in murine colons. Cancer Res 1988; 48(21): 6183–6PubMedGoogle Scholar
  21. 21.
    McLellan EA, Bird RP. Aberrant crypts: potential preneoplastic lesions in the murine colon. Cancer Res 1988; 48(21): 6187–92PubMedGoogle Scholar
  22. 22.
    McLellan EA, Medline A, Bird RP. Dose response and proliferative characteristics of aberrant crypt foci: putative preneoplastic lesions in rat colon. Carcinogenesis 1991; 12(11): 2093–8PubMedCrossRefGoogle Scholar
  23. 23.
    McLellan EA, Medline A, Bird RP. Sequential analyses of the growth and morphological characteristics of aberrant crypt foci: putative preneoplastic lesions. Cancer Res 1991; 51(19): 5270–4PubMedGoogle Scholar
  24. 24.
    McLellan E, Bird RP. Effect of disulfiram on 1,2-dimethylhydrazine- and azoxymethane-induced aberrant crypt foci. Carcinogenesis 1991; 12(6): 969–72PubMedCrossRefGoogle Scholar
  25. 25.
    Magnuson BA, Carr I, Bird RP. Ability of aberrant crypt foci characteristics to predict colonic tumor incidence in rats fed cholic acid. Cancer Res 1993; 53(19): 4499–504PubMedGoogle Scholar
  26. 26.
    Lam LK, Zhang J. Reduction of aberrant crypt formation in the colon of CF1 mice by potential chemopreventive agents. Carcinogenesis 1991; 12(12): 2311–5PubMedCrossRefGoogle Scholar
  27. 27.
    Corpet DE, Tache S. Most effective colon cancer chemopreventive agents in rats: a systematic review of aberrant crypt foci and tumor data, ranked by potency. Nutr Cancer 2002; 43(1): 1–21PubMedCrossRefGoogle Scholar
  28. 28.
    Shpitz B, Bomstein Y, Mekori Y, et al. Aberrant crypt foci in human colons: distribution and histomorphologic characteristics. Hum Pathol 1998; 29(5): 469–75PubMedCrossRefGoogle Scholar
  29. 29.
    Roncucci L, Stamp D, Medline A, et al. Identification and quantification of aberrant crypt foci and microadenomas in the human colon. Hum Pathol 1991; 22(3): 287–94PubMedCrossRefGoogle Scholar
  30. 30.
    Takayama T, Katsuki S, Takahashi Y, et al. Aberrant crypt foci of the colon as precursors of adenoma and cancer. N Engl J Med 1998; 339(18): 1277–84PubMedCrossRefGoogle Scholar
  31. 31.
    Moxon D, Raza M, Kenney R, et al. Relationship of aging and tobacco use with the development of aberrant crypt foci in a predominantly African-American population. Clin Gastroenterol Hepatol 2005; 3(3): 271–8PubMedCrossRefGoogle Scholar
  32. 32.
    Adler DG, Gostout CJ, Sorbi D, et al. Endoscopic identification and quantification of aberrant crypt foci in the human colon. Gastrointest Endosc 2002; 56(5): 657–62PubMedCrossRefGoogle Scholar
  33. 33.
    Rudolph RE, Dominitz JA, Lampe JW, et al. Risk factors for colorectal cancer in relation to number and size of aberrant crypt foci in humans. Cancer Epidemiol Biomarkers Prev 2005; 14(3): 605–8PubMedCrossRefGoogle Scholar
  34. 34.
    Seike K, Koda K, Oda K, et al. Assessment of rectal aberrant crypt foci by standard chromoscopy and its predictive value for colonic advanced neoplasms. Am J Gastroenterol 2006; 101(6): 1362–9PubMedCrossRefGoogle Scholar
  35. 35.
    Stevens RG, Swede H, Heinen CD, et al. Aberrant crypt foci in patients with a positive family history of sporadic colorectal cancer. Cancer Lett 2007 Apr 18; 248(2): 262–8PubMedCrossRefGoogle Scholar
  36. 36.
    Bouzourene H, Chaubert P, Seelentag W, et al. Aberrant crypt foci in patients with neoplastic and nonneoplastic colonic disease. Hum Pathol 1999; 30(1): 66–71PubMedCrossRefGoogle Scholar
  37. 37.
    Siu IM, Pretlow TG, Amini SB, et al. Identification of dysplasia in human colonic aberrant crypt foci. Am J Pathol 1997; 150(5): 1805–13PubMedGoogle Scholar
  38. 38.
    Osborn NK, Ahlquist DA. Stool screening for colorectal cancer: molecular approaches. Gastroenterology 2005; 128(1): 192–206PubMedCrossRefGoogle Scholar
  39. 39.
    Sidransky D, Tokino T, Hamilton SR, et al. Identification of ras oncogene mutations in the stool of patients with curable colorectal tumors. Science 1992; 256(5053): 102–5PubMedCrossRefGoogle Scholar
  40. 40.
    Traverso G, Shuber A, Levin B, et al. Detection of APC mutations in fecal DNA from patients with colorectal tumors. N Engl J Med 2002; 346(5): 311–20PubMedCrossRefGoogle Scholar
  41. 41.
    Ahlquist DA, Skoletsky JE, Boynton KA, et al. Colorectal cancer screening by detection of altered human DNA in stool: feasibility of a multitarget assay panel. Gastroenterology 2000; 119(5): 1219–27PubMedCrossRefGoogle Scholar
  42. 42.
    Tagore KS, Lawson MJ, Yucaitis JA, et al. Sensitivity and specificity of a stool DNA multitarget assay panel for the detection of advanced colorectal neoplasia. Clin Colorectal Cancer 2003; 3(1): 47–53PubMedCrossRefGoogle Scholar
  43. 43.
    Petko Z, Ghiassi M, Shuber A, et al. Aberrantly methylated CDKN2A, MGMT, and MLH1 in colon polyps and in fecal DNA from patients with colorectal polyps. Clin Cancer Res 2005; 11(3): 1203–9PubMedGoogle Scholar
  44. 44.
    Song K, Fendrick AM, Ladabaum U. Fecal DNA testing compared with conventional colorectal cancer screening methods: a decision analysis. Gastroenterology 2004; 126(5): 1270–9PubMedCrossRefGoogle Scholar
  45. 45.
    Brenner DE, Rennert G. Fecal DNA biomarkers for the detection of colorectal neoplasia: attractive, but is it feasible? J Natl Cancer Inst 2005; 97(15): 1107–9PubMedCrossRefGoogle Scholar
  46. 46.
    Hundt S, Haug U, Brenner H. Blood markers for early detection of colorectal cancer: a systematic review. Cancer Epidemiol Biomarkers Prev 2007; 16(10): 1935–53PubMedCrossRefGoogle Scholar
  47. 47.
    Fletcher RH. Carcinoembryonic antigen. Ann Intern Med 1986; 104(1): 66–73PubMedGoogle Scholar
  48. 48.
    Kozwich DL, Kramer LC, Mielicki WP, et al. Application of cancer procoagulant as an early detection tumor marker. Cancer 1994; 74(4): 1367–76PubMedCrossRefGoogle Scholar
  49. 49.
    Cordero OJ, Ayude D, Nogueira M, et al. Preoperative serum CD26 levels: diagnostic efficiency and predictive value for colorectal cancer. Br J Cancer 2000; 83(9): 1139–46PubMedCrossRefGoogle Scholar
  50. 50.
    de la Haba-Rodriguez J, Macho A, Calzado MA, et al. Soluble dipeptidyl peptidase IV (CD-26) in serum of patients with colorectal carcinoma. Neoplasma 2002; 49(5): 307–11Google Scholar
  51. 51.
    Kerber A, Trojan J, Herrlinger K, et al. The new DR-70 immunoassay detects cancer of the gastrointestinal tract: a validation study. Aliment Pharmacol Ther 2004; 20(9): 983–7PubMedCrossRefGoogle Scholar
  52. 52.
    Soroush AR, Zadeh HM, Moemeni M, et al. Plasma prolactin in patients with colorectal cancer. BMC Cancer 2004; 4: 97PubMedCrossRefGoogle Scholar
  53. 53.
    Fedarko NS, Jain A, Karadag A, et al. Elevated serum bone sialoprotein and osteopontin in colon, breast, prostate, and lung cancer. Clin Cancer Res 2001; 7(12): 4060–6PubMedGoogle Scholar
  54. 54.
    Leman ES, Schoen RE, Weissfeld JL, et al. Initial analyses of colon cancer-specific antigen (CCSA)-3 and CCSA-4 as colorectal cancer-associated serum markers. Cancer Res 2007; 67(12): 5600–5PubMedCrossRefGoogle Scholar
  55. 55.
    Ward DG, Suggett N, Cheng Y, et al. Identification of serum biomarkers for colon cancer by proteomic analysis. Br J Cancer 2006; 94(12): 1898–905PubMedCrossRefGoogle Scholar
  56. 56.
    de Noo ME, Deelder A, van der Werff M, et al. MALDI-TOF serum protein profiling for the detection of breast cancer. Onkologie 2006; 29(11): 501–6CrossRefGoogle Scholar
  57. 57.
    Ransohoff DF. Bias as a threat to the validity of cancer molecular-marker research. Nat Rev Cancer 2005; 5(2): 142–9PubMedCrossRefGoogle Scholar
  58. 58.
    Ransohoff DF. Colon cancer screening in 2005: status and challenges. Gastroenterology 2005; 128(6): 1685–95PubMedCrossRefGoogle Scholar
  59. 59.
    Zhao J, Qiu W, Simeone DM, et al. N-linked glycosylation profiling of pancreatic cancer serum using capillary liquid phase separation coupled with mass spec-trometric analysis. J Proteome Res 2007; 6(3): 1126–38PubMedCrossRefGoogle Scholar
  60. 60.
    Zhu Y, Wu R, Sangha N, et al. Classifications of ovarian cancer tissues by proteomic patterns. Proteomics 2006; 6(21): 5846–56PubMedCrossRefGoogle Scholar
  61. 61.
    Tataryn DN, MacFarlane JK, Murray D, et al. Tube leukocyte adherence inhibition (LAI) assay in gastrointestinal (GIT) cancer. Cancer 1979; 43(3): 898–912PubMedCrossRefGoogle Scholar
  62. 62.
    Liu HP, Yan ZS, Zhang SS. The application of leukocyte adherence inhibition assay to patients with colorectal cancer: comparison with serum level of carcinoembryonic antigen and sialic acid. Dis Colon Rectum 1989; 32(3): 210–3PubMedCrossRefGoogle Scholar
  63. 63.
    Wang RF, Kim SJ, Robertson LH, et al. Development of a membrane-array method for the detection of human intestinal bacteria in fecal samples. Mol Cell Probes 2002; 16(5): 341–50PubMedCrossRefGoogle Scholar
  64. 64.
    Kopreski MS, Benko FA, Borys DJ, et al. Somatic mutation screening: identification of individuals harboring K-ras mutations with the use of plasma DNA. J Natl Cancer Inst 2000; 92(11): 918–23PubMedCrossRefGoogle Scholar
  65. 65.
    Wang JY, Hsieh JS, Chang MY, et al. Molecular detection of APC, K-ras, and p53 mutations in the serum of colorectal cancer patients as circulating biomarkers. World J Surg 2004; 28(7): 721–6PubMedCrossRefGoogle Scholar
  66. 66.
    Leung WK, To KF, Man EP, et al. Quantitative detection of promoter hypermethylation in multiple genes in the serum of patients with colorectal cancer. Am J Gastroenterol 2005; 100(10): 2274–9PubMedCrossRefGoogle Scholar
  67. 67.
    Umetani N, Kim J, Hiramatsu S, et al. Increased integrity of free circulating DNA in sera of patients with colorectal or periampullary cancer: direct quantitative PCR for ALU repeats. Clin Chem 2006; 52(6): 1062–9PubMedCrossRefGoogle Scholar
  68. 68.
    Bustin SA, Gyselman VG, Williams NS, et al. Detection of cytokeratins 19/20 and guanylyl cyclase C in peripheral blood of colorectal cancer patients. Br J Cancer 1999; 79(11–12): 1813–20PubMedCrossRefGoogle Scholar
  69. 69.
    Schiedeck TH, Wellm C, Roblick UJ, et al. Diagnosis and monitoring of colorectal cancer by L6 blood serum polymerase chain reaction is superior to carcinoembryonic antigen-enzyme-linked immunosorbent assay. Dis Colon Rectum 2003; 46(6): 818–25PubMedCrossRefGoogle Scholar

Copyright information

© Adis Data Information BV 2008

Authors and Affiliations

  • Akshay K. Gupta
    • 1
  • Dean E. Brenner
    • 2
  • D. Kim Turgeon
    • 1
  1. 1.Division of Gastroenterology, Department of Internal MedicineUniversity of Michigan Medical SchoolAnn ArborUSA
  2. 2.Division of Hematology-Oncology, Department of Internal MedicineUniversity of Michigan Medical SchoolAnn ArborUSA

Personalised recommendations